日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial

结直肠癌辅助奥沙利铂-氟尿嘧啶化疗3个月与6个月的比较:SCOT国际随机III期非劣效性试验的最终结果

Iveson, Timothy; Saunders, Mark P; Kelly, Caroline; Kerr, Rachel S; Cassidy, Jim; Hollander, Niels Henrik; Tabernero, Josep; Haydon, Andrew; Glimelius, Bengt; Harkin, Andrea; Allan, Karen; McQueen, John; Pearson, Sarah; Boyd, Kathleen A; Briggs, Andrew H; Waterston, Ashita; Medley, Louise; Ellis, Richard; Dhadda, Amandeep S; Harrison, Mark; Falk, Stephen; Rees, Charlotte; Olesen, Rene K; Propper, David; Bridgewater, John; Azzabi, Ashraf; Cunningham, David; Hickish, Tamas; Gollins, Simon; Wasan, Harpreet S; Church, David; Domingo, Enric

Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical Trial

从结直肠癌手术到辅助化疗的时间:SCOT随机临床试验的事后分析

Gögenur, Mikail; Rosen, Andreas Weinberger; Iveson, Timothy; Kerr, Rachel S; Saunders, Mark P; Cassidy, Jim; Tabernero, Josep; Haydon, Andrew; Glimelius, Bengt; Harkin, Andrea; Allan, Karen; Pearson, Sarah; Boyd, Kathleen A; Briggs, Andrew H; Waterston, Ashita; Medley, Louise; Ellis, Richard; Dhadda, Amandeep S; Harrison, Mark; Falk, Stephen; Rees, Charlotte; Olesen, Rene K; Propper, David; Bridgewater, John; Azzabi, Ashraf; Cunningham, David; Hickish, Tamas; Gollins, Simon; Wasan, Harpreet S; Kelly, Caroline; Gögenur, Ismail; Holländer, Niels Henrik

Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer

早期三阴性乳腺癌中循环肿瘤 DNA 检测方法对分子残留疾病检测的比较

Maria Coakley, Guillermo Villacampa, Prithika Sritharan, Claire Swift, Kathryn Dunne, Lucy Kilburn, Katie Goddard, Christodoulos Pipinikas, Patricia Rojas, Warren Emmett, Peter Hall, Catherine Harper-Wynne, Tamas Hickish, Iain Macpherson, Alicia Okines, Andrew Wardley, Duncan Wheatley, Simon Waters,

A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer

英国前瞻性多中心研究:21基因检测在淋巴结阳性、激素受体阳性、HER2阴性乳腺癌女性患者中的决策影响、决策冲突和经济性评估

Holt, Simon; Verrill, Mark; Pettit, Laura; Rigg, Anna; Hickish, Tamas; Archer, Caroline; Dent, Jo; Dillon, Marianne; Nathan, Mark; Barthelmes, Ludger; Rehman, Shazza; Sharaiha, Yousef; Innis, Paige; Sai-Giridhar, Priya; Khawaja, Saira

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

奥拉帕尼和塞拉塞替(AZD6738)治疗三阴性晚期乳腺癌患者:plasmaMATCH试验E组的结果(CRUK/15/010)

Ring, Alistair; Kilburn, Lucy S; Pearson, Alex; Moretti, Laura; Afshari-Mehr, Angelica; Wardley, Andrew M; Gurel, Bora; Macpherson, Iain R; Riisnaes, Ruth; Baird, Richard D; Martin, Sue; Roylance, Rebecca; Johnson, Hannah; Ferreira, Ana; Winter, Matthew C; Dunne, Kathryn; Copson, Ellen; Hickish, Tamas; Burcombe, Russell; Randle, Kat; Serra, Violeta; Llop-Guevara, Alba; Bliss, Judith M; Turner, Nicolas C

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial

在既往接受曲妥珠单抗和/或拉帕替尼治疗失败或疾病进展的HER2阳性乳腺癌患者中,阿法替尼单药治疗以及联合长春瑞滨或紫杉醇治疗的疗效(LUX-Breast 2):一项开放标签、多中心、II期临床试验

Hickish, Tamas; Mehta, Ajay; Liu, Mei-Ching; Huang, Chiun-Sheng; Arora, Rajendra Singh; Chang, Yuan-Ching; Yang, Youngsen; Vladimirov, Vladimir; Jain, Minish; Tsang, Janice; Pemberton, Karine; Sadrolhefazi, Behbood; Jin, Xidong; Tseng, Ling-Ming

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial

术后CEA水平与II期结肠癌患者生存率和奥沙利铂疗效的相关性:MOSAIC试验的事后分析

Auclin, Edouard; André, Thierry; Taieb, Julien; Banzi, Maria; Van Laethem, Jean-Luc; Tabernero, Josep; Hickish, Tamas; de Gramont, Aimery; Vernerey, Dewi

Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer

在一项针对晚期结直肠癌的III期随机研究中,白细胞介素-1受体拮抗剂水平可预测bermekimab(一种首创的真正人源白细胞介素-1α抗体)治疗后的良好预后。

Kurzrock, Razelle; Hickish, Tamas; Wyrwicz, Lucjan; Saunders, Mark; Wu, Qian; Stecher, Michael; Mohanty, Prasant; Dinarello, Charles A; Simard, John

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial

对于 HER2 阴性早期乳腺癌女性患者,新辅助贝伐珠单抗联合多西他赛,随后序贯氟尿嘧啶、表柔比星和环磷酰胺治疗,3.5 年无病生存率和总生存率:ARTemis 试验

Earl, H M; Hiller, L; Dunn, J A; Blenkinsop, C; Grybowicz, L; Vallier, A-L; Gounaris, I; Abraham, J E; Hughes-Davies, L; McAdam, K; Chan, S; Ahmad, R; Hickish, T; Rea, D; Caldas, C; Bartlett, J M S; Cameron, D A; Provenzano, E; Thomas, J; Hayward, R L

Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer

肿瘤组织学亚型对晚期食管癌化疗疗效的影响

Davidson, Michael; Chau, Ian; Cunningham, David; Khabra, Komel; Iveson, Timothy; Hickish, Tamas; Seymour, Matthew; Starling, Naureen